186 related articles for article (PubMed ID: 8388498)
1. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence.
Shimizu N; Takada K
J Virol; 1993 Jun; 67(6):3240-5. PubMed ID: 8388498
[TBL] [Abstract][Full Text] [Related]
2. Negatively cis-acting elements in the distal part of the promoter of Epstein-Barr virus trans-activator gene BZLF1.
Schwarzmann F; Prang N; Reichelt B; Rinkes B; Haist S; Marschall M; Wolf H
J Gen Virol; 1994 Aug; 75 ( Pt 8)():1999-2006. PubMed ID: 8046403
[TBL] [Abstract][Full Text] [Related]
3. Negative regulation of the BZLF1 promoter of Epstein-Barr virus.
Montalvo EA; Shi Y; Shenk TE; Levine AJ
J Virol; 1991 Jul; 65(7):3647-55. PubMed ID: 1645787
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.
Le Roux F; Sergeant A; Corbo L
J Gen Virol; 1996 Mar; 77 ( Pt 3)():501-9. PubMed ID: 8601788
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
[TBL] [Abstract][Full Text] [Related]
7. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.
Hergenhahn M; Soto U; Weninger A; Polack A; Hsu CH; Cheng AL; Rösl F
Mol Carcinog; 2002 Mar; 33(3):137-45. PubMed ID: 11870879
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells.
Daibata M; Speck SH; Mulder C; Sairenji T
Virology; 1994 Feb; 198(2):446-54. PubMed ID: 8291228
[TBL] [Abstract][Full Text] [Related]
9. Identification of an enhancer-type sequence that is responsive to Z and R trans-activators of Epstein-Barr virus.
Shimizu N; Sakuma S; Ono Y; Takada K
Virology; 1989 Oct; 172(2):655-8. PubMed ID: 2552665
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.
Fahmi H; Cochet C; Hmama Z; Opolon P; Joab I
J Virol; 2000 Jul; 74(13):5810-8. PubMed ID: 10846060
[TBL] [Abstract][Full Text] [Related]
11. Histone acetylation and reactivation of Epstein-Barr virus from latency.
Jenkins PJ; Binné UK; Farrell PJ
J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
[TBL] [Abstract][Full Text] [Related]
12. CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle.
Wu FY; Wang SE; Chen H; Wang L; Hayward SD; Hayward GS
J Virol; 2004 May; 78(9):4847-65. PubMed ID: 15078966
[TBL] [Abstract][Full Text] [Related]
13. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.
Zhang Q; Hong Y; Dorsky D; Holley-Guthrie E; Zalani S; Elshiekh NA; Kiehl A; Le T; Kenney S
J Virol; 1996 Aug; 70(8):5131-42. PubMed ID: 8764021
[TBL] [Abstract][Full Text] [Related]
14. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
15. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions.
Lieberman PM; Hardwick JM; Sample J; Hayward GS; Hayward SD
J Virol; 1990 Mar; 64(3):1143-55. PubMed ID: 2154599
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
Gradoville L; Kwa D; El-Guindy A; Miller G
J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin.
Goldfeld AE; Liu P; Liu S; Flemington EK; Strominger JL; Speck SH
Virology; 1995 May; 209(1):225-9. PubMed ID: 7538254
[TBL] [Abstract][Full Text] [Related]
19. Identification of an epithelial cell differentiation responsive region within the BZLF1 promoter of the Epstein-Barr virus.
Karimi L; Crawford DH; Speck S; Nicholson LJ
J Gen Virol; 1995 Apr; 76 ( Pt 4)():759-65. PubMed ID: 9049321
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection.
Sista ND; Pagano JS; Liao W; Kenney S
Proc Natl Acad Sci U S A; 1993 May; 90(9):3894-8. PubMed ID: 8387200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
